Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Q2 2023 Earnings Presentation
26 slides from Swedish Orphan Biovitrum Ab's earnings presentation, Jul 18, 2023
Slide 1: Growth and pipeline expansion
Growth and pipeline expansion Sobi Q2 2023 results Conference call for investors and analysts 18 July 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer Pipeline Armin Reininger, Senior Scientific and Medical Advisor Summary and Q&A 3
Slide 4: Successfully delivering on the strategy
Successfully delivering on the strategy Q2 2023 highlights Sobi strategy Significant growth Q2 revenue SEK 4,872 M, up +26% (+16% CER) Lead in H1 revenue SEK 10,111 M, up +15% (+6% CER) Haematology Building the leading rare haematology franchise Acquisition of CTI / Vonjo® Capture the value Accelera
Slide 5: Sobi is excited to add Vonjo to its haematology franchise
Sobi is excited to add Vonjo® to its haematology franchise Vonjo® has a Severe differentiated profile in thrombocytopenic MF myelofibrosis (MF) represents an unmet clinical need Combined leadership with CTI Biopharma Complementary Expectation: highly haematology reach and accretive to Sobi’s experti
Slide 6: Well-prepared CTI integration capturing Vonjo's value
Well-prepared CTI integration capturing Vonjo’s value Positive and smooth first two weeks focused on seamless continuation of Vonjo operations Life-cycle management planning initiated for geographic expansion and extended indications Thoughtful strategy to maximize Vonjo’s 1+1=3 potential and synerg
Slide 7: Pacritinib is well positioned for growth and further exploration of its benefits
Pacritinib is well positioned for growth and further exploration of its benefits Sobi KOL Real world investor event insights 19 July 2023 15:30 CET John Mascarenhas, Professor of Medicine, Icahn School of Medicine at Mount Sinai New Sarah Buckley, Medicine indications Development Lead Vonjo Guido Oe
Slide 8: Sobi intends to carry out a rights issue – EGM on August 15
Sobi intends to carry out a rights issue – Extraordinary General Meeting (EGM) on August 15 • SEK 6bn rights issue with preferential rights for Declared intention, shareholders to be launched after EGM share of total shares* Undertaking Investor AB, 36.2% • Proceeds to be used to pay back part of th
Slide 9: Business growth at CER of 16%
Business growth at CER of 16% Strong performance in both Haematology and Immunology, especially for our launch medicines H1: +9% at CER, excluding Covid-19 effect for Kineret and Doptelet partnering in China Revenue by segment Revenue by region Q2 ’23 change H1 ’23 change contrib. Q2 ’23 change H1 ’
Slide 10: Rich growth portfolio and robust late-stage pipeline
Rich growth portfolio and robust late-stage pipeline Accelerated Phase Phase 3 Submission Launch growth phase Portfolio Aspaveli with Efanesoc- (C3/IC- Zynlonta Doptelet realized tocog alfa MPGN) growth potential SEL-212 Vonjo Gamifant Share of realized potential for illustration purposes Beyfortus
Slide 11: Haematology: Continued stable haemophilia growth with revenues YTD +2%
Haematology: Continued stable haemophilia growth with revenues YTD +2% Elocta® Elocta Alprolix® -5% Q2 +0% Q2 +2% H1 • Strong underlying unit growth +8% H1 in International markets – phasing less favourable in Q2 • Government interventions compress prices in various European markets. • Positive evol
Slide 12: Haematology: Doptelet up 74%. +59% excluding China
Haematology: Doptelet up 74%. +59% excluding China. Increased US uptake, launches in Europe and International Doptelet +74% Q2 • US: positive evolution of new +24% H1 patients, new prescribers, higher market share and duration of treatment • Europe: accelerated growth in Europe and International; Ke
Slide 13: Aspaveli launch: SEK 144 M in Q2 2023
CONFIDENTIAL – FOR INTERNAL USE ONLY Launching in Germany, UK, France, Italy, Spain, Belgium, Luxembourg, Australia, Croatia, Finland, Greece, Netherlands, Switzerland, Saudi Arabia, Austria, Denmark2, Hungary, Sweden, Canada3 SEK 144 M launching in Sobi in Q2 2023 sales territories for PNH1 ~190 pe
Slide 14: Immunology: Improved Gamifant strategy pays off, Kineret with increased demand
Immunology: Improved Gamifant strategy pays off, Kineret with increased demand after Covid effect in Q1 Gamifant Kineret +73% Q2 Gamifant +12% Q2 +45% H1 -7% H1 • Enhanced outreach and new data improves familiarity with prescribers, adds more patients for longer • Higher average patient weight incre
Slide 15: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer Pipeline Armin Reininger, Senior Scientific and Medical Advisor Summary and Q&A 15
Slide 16: Q2 2023 Revenue and profit & loss
Q2 2023 Revenue and profit & loss Q2 Q2 Full-year Total revenue (SEK M) Amounts in SEK M 2023 2022 Change 2022 Total revenue 4,872 3,876 26% 18,790 Haematology Immunology Specialty Care 1,2 3,478 2,859 22% 14,014 Gross profit adjusted Gross margin adjusted 1,2 71% 74% 75% 5 991 323 EBITA1,2 1,009 94
Slide 17: Outlook 2023 – updated
Outlook 2023 – updated Revenue New: Anticipated to grow by a high-single-digit percentage at CER1 EBITA margin adjusted2 Anticipated to be at a low 30s percentage of revenue (unchanged) Outlook includes the newly acquired company CTI and Sobi’s right to royalty on net sales of nirsevimab in the US 1
Slide 18: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer Pipeline Armin Reininger, Senior Scientific and Medical Advisor Summary and Q&A 18
Slide 19: Key pipeline achievements move late-stage forward
Key pipeline achievements move late-stage forward Efanesoctocog alfa Nirsevimab Haemophilia A RSV EMA validates marketing authorisation application On July 17, the FDA approved Paediatric data presented at Sanofi and AstraZeneca’s ISTH late-breaker session Beyfortus (nirsevimab-alip) for the prevent
Slide 20: Increasing R&D pipeline news flow
Increasing R&D pipeline news flow Anticipated major upcoming pipeline news flow H2 2023 2024 Doptelet – ITP1: regulatory decision Aspaveli/Empaveli – C3G4 and in China IC-MPGN4: VALIANT phase 3 study data readout Gamifant – MAS2 in rheumatological diseases: EMERALD phase 3 study Aspaveli/Empaveli –
Slide 21: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer Pipeline Armin Reininger, Senior Scientific and Medical Advisor Summary and Q&A 21
Slide 22: Sobi's rare strength to deliver
Sobi’s rare strength to deliver Clear Strong Cohesive strategy performance culture leadership team 22
Slide 23: Summary: Growth and pipeline expansion
Summary: Growth and pipeline expansion Revenue Q1: +26% (+16% CER) Significant growth Revenue H1: +15% (+6% CER) Expanded position CTI / Vonjo in Haematology Key milestones Efanesoctocog alfa for late-stage pipeline Nirsevimab Increase of guidance High single-digit growth 23
Slide 24: sob!
sob! Kt
Slide 25: Appendix: Q2 2023 sustainability performance
Appendix: Q2 2023 sustainability performance Sobi sustainability priorities Highlights in Q2 2023 Highlights in Q2 2023 • Milestones toward increased access • Caring for employees - Zynlonta (loncastuximab teserine) - Further deployment of Sobi’s launched in EU for treatment of DLBCL. leadership com
Slide 26: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2022 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum — Q2 2023 Earnings Presentation on 6ix